Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Bitterroot Bio kickstarts Phase I trial for cardiovascular disease candidate [Yahoo! Finance]
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors [Yahoo! Finance]
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $45.00 price target on the stock.